dual orexin receptor antagonist developed glaxosmithkline treatment phase clinical trial evaluated doses mg resulting significant improvement sleep latency without adverse randomized doubleblind placebocontrolled crossover trials mg doses increased sleep time reduced sleep subsequent phase ii study added mg dose observed dosedependent sleep compound longer appears active development last study posted clinicaltrialsgov completed sedativerelated article stub help wikipedia expanding